ICON Announces Details of New Translational Medicine Unit in Manchester
Dublin, Ireland
ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, announced details of its new translational medicine unit in Manchester, UK. The unit is the first deliverable from a collaborative agreement between ICON and the Central Manchester University Hospitals Foundation (CMFT) to develop purpose-built translational medicine facilities on the newly-developed Manchester Royal Infirmary (MRI) campus.
Scheduled to open in April 2010, the new hospital-based unit will comprise of 34 beds, an on-site GMP pharmacy, a sample handling laboratory, multiple meeting and admissions rooms and has contiguous access to the Accident and Emergency department at the MRI. The unit will also offer Pharmacodynamic study testing suites that are fully environmentally controlled, which will be used in the development and validation of Pharmacodynamic models that assist in identifying efficacy signals in compounds.
“We are delighted to be collaborating with a partner who shares our vision for early-stage clinical development and are proud to be developing our...translational medicine facility at the CMFT campus,” commented Dr. Thomas Frey, President, ICON Development Solutions.
CMFT is a member of the Manchester Academic Health Science Centre (MAHSC) which is one of only five such sites in the UK designated by the Department of Health. as a centre in applying health research and education into healthcare. Through the collaboration, ICON will share expertise with academic and medical communities of this network and has access to the facilities of the other NHS members and the University of Manchester.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
